Conferences - Results from #8240

ASCO GU 2016 Best of Journals: Prostate Cancer Medical Oncology - Session Highlights January 8, 2016

ASCO GU 2016 Best of Journals: Prostate Cancer Surgical Oncology - Session Highlights January 8, 2016

ASCO GU 2016 Best of Journals: Prostate Cancer Radiation Oncology - Session Highlights January 8, 2016

ASCO GU 2016 Changes in the Treatment of Hormone-Naïve Metastatic Prostate Cancer - Session Highlights January 8, 2016

ASCO GU 2016 Evaluating PSA nadir drift in high-risk and metastatic prostate cancer. - Poster Session Highlights January 8, 2016

ASCO GU 2016 Prostate Cancer: Year in Review - Session Highlights January 8, 2016

ASCO GU 2016 Best Use of Approved Therapies for Bone Metastases - Session Highlights January 8, 2016

ASCO GU 2016 Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases January 7, 2016

ASCO GU 2016 – Oral Abstract Session: NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following (RP) and an elevated PSA. - Session Highl January 7, 2016

ASCO GU 2016 Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476). – Poster Session Highlights January 7, 2016

ASCO GU 2016 Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial. – Session Highlights January 7, 2016

ASCO GU 2016 Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. – Poster Session Highlights January 7, 2016

ASCO GU 2016 Cardiovascular events in prostate cancer patients: A comparative analysis of German claims data. - Poster Session Highlights January 7, 2016

ASCO GU 2016 ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer. - Poster Session Highlights January 7, 2016

ASCO GU 2016 Novel Targets for Castrate-Resistant Prostate Cancer - Session Highlights January 7, 2016

ASCO GU 2016 Effects of PSA screening guidelines on trends of diagnosis and treatment for prostate cancer: Analysis from the National Cancer Data Base (NCDB). - Poster Session Highlights January 7, 2016

ASCO GU 2016 Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (its). - Session Highlights January 7, 2016

ASCO GU 2016 Application of Active Surveillance Threshold to Series of Samples Submitted for Commercial Testing - Poster January 7, 2016

ASCO GU 2016 Prognostic utility of a multi-gene signature (the cell cycle proliferation score) in patients with renal cell carcinoma (RCC) after radical nephrectomy - Poster January 7, 2016

ASCO GU 2016 Androgen Receptor: New Ways of Targeting the Old Target - Session Highlights January 7, 2016

Page 413 of 492

email news signup